10-K/A

_____________________________________________________________________________

                    SECURITIES AND EXCHANGE COMMISSION
                         Washington, D.C.  20549
                 

                               Form 10-K
                Annual Report Pursuant to Section 13 or 15(d)
                    of the Securities Exchange Act of 1934
                 

FOR THE FISCAL YEAR ENDED                         COMMISSION FILE NUMBER
  December 31, 1994                                      0-12248

                            Daxor Corporation
             (Exact name of Registrant as specified in its charter)

          New York                                13-2682108
(State or other jurisdiction of                 (IRS Employer
incorporation or organization)               Identification Number)

                              350 Fifth Avenue
                                 Suite 7120
                           New York, New York  10118
               (Address of principal executive offices) (Zip Code)

                  Registrant's telephone number: (212) 244-0555

           Securities registered pursuant to Section 12(b) of the Act:
                      Common Shares, $.01 par value
                             (Title of Class)

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark whether Registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934
during the preceding 12 months and (2) has been subject to such filing
requirements for the past 90 days.
                          
                             Yes (X)             No ( )

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-X is not contained herein, and will not be contained, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to
this form 10-K.  [  ]   

                                     
As at March 28, 1995, the aggregate market value of the voting stock held by
non-affiliates of the Registrant was $ 12,405,494. The market value of Common
Stock of the Registrant, par value $.01 per share, was computed by reference
to the closing price of one share on such date, as reported by the American
Stock Exchange, which was $ 6.75.

                                    
The number of shares outstanding of the Registrant's Common Stock, par value
$.01 per share, as of March 28, 1995:  5,067,630 shares.

                                     
Documents incorporated by reference:  The information required by Part III is
incorporated by reference from the proxy statement for the 1994 Annual Meeting
of Shareholders.


Signature

Pursuant to the requirements of Section 13 or 15(d) of the
Securities and Exchange Act of 1934, the Registrant has duly caused
this report to be signed on its behalf by the undersigned, thereto
duly authorized.


DAXOR CORPORATION



by:

/s/ Joseph Feldschuh M.D.
Joseph Feldschuh, M.D.
Chairman, President
and Chief Executive Officer


Dated: 4/19/95                

Pusuant to the requirements of the Securities Exchange Act of
1934, this report has been signed below by the following persons on
behalf of the Registrant and in the capacities and on the dates
indicated.


Signature                            Title                       Date 
      
/s/ Joseph Feldschuh MD      President and Director         May 19, 1995
Joseph Feldschuh, M.D.       (Principal Executive Officer)







Item 14(a) (1).   Index to Financial Statements


The following statements and schedules of Daxor Corporation are
submitted herewith:




                                                       
                                                                          Page

Report of Independent Accountants...................................      F-1

Consolidated Financial Statements as at December 31, 1994 and 1993 
  and for the three years ended  December 31, 1992
     Consolidated Balance Sheets....................................      F-2
     Consolidated Statements of Income..............................      F-3
     Consolidated Statements of Shareholders' Equity................      F-3
     Consolidated Statements of Cash Flows..........................      F-4

Notes to Financial Statements.......................................      F-5

Schedule I - Marketable Securities - Other Investments - Year ended
  December 31, 1994.................................................      F-9

Schedule IX - Short-term Borrowings - Years ended December 31, 1994
  1993, and 1992....................................................      F-9

Schedule X - Supplementary Income Statement Information - 
Years ended December 31, 1994, 1993, and 1992.......................      F-9


Exhibit 27 - Supplementary exhibit as reguired by the Securities 
             and Exchange Commission................................ Exhibit 2


All other schedules for which provision is made in the applicable
accounting regulations of the Securities and Exchange Commission are
not required under the related instructions, are inapplicable or the
required information is set forth in the financial statements filed
herewith, including notes thereto, and therefore have been omitted.

EX-27

 

<ARTICLE> 5
<MULTIPLIER> 1
       
                             
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1994
<PERIOD-END>                               DEC-31-1994
<CASH>                                          59,962
<SECURITIES>                                33,598,931
<RECEIVABLES>                                  215,831
<ALLOWANCES>                                         0
<INVENTORY>                                    158,000
<CURRENT-ASSETS>                            34,553,264
<PP&E>                                         998,019      
<DEPRECIATION>                               (579,805)
<TOTAL-ASSETS>                              35,012,638
<CURRENT-LIABILITIES>                        5,813,458
<BONDS>                                              0
<COMMON>                                        53,097
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<OTHER-SE>                                  29,146,083
<TOTAL-LIABILITY-AND-EQUITY>                35,012,638
<SALES>                                      1,844,418
<TOTAL-REVENUES>                             4,587,135
<CGS>                                        1,016,832       
<TOTAL-COSTS>                                2,613,481
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              11,116
<INCOME-PRETAX>                              1,973,654
<INCOME-TAX>                                   165,519
<INCOME-CONTINUING>                          1,808,135
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 1,808,135
<EPS-PRIMARY>                                      .35
<EPS-DILUTED>                                      .35